In line with the Company’s Fix, Fund, Propel
approach, Jill Bieker Stefanelli, Ph.D. joins Board, adding
precision medicine and product development depth in support of
stated strategy to advance innovative technology to market.
Separately, Alexander L. Cappello steps down.
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB)
(“Navidea” or the “Company”), a company focused on the development
of precision immunodiagnostic agents and immunotherapeutics, today
announced Jill Bieker Stefanelli, Ph.D. has joined the Company’s
Board of Directors, adding deep experience developing and advancing
precision medicine products in line with Navidea’s stated
objectives and its Fix, Fund, Propel approach to advancing
innovative technology to market. Separately, Alexander L. Cappello
has stepped down from the Company’s Board.
Results-Driven, Experienced, Precision Medicine Leader and
Strategist
Jill Bieker Stefanelli, Ph.D. joins Navidea’s Board of Directors
with demonstrated experience leading fast-paced organizations
focused on transformative precision medicine. Dr. Stefanelli’s
career and expertise within pharma and commercial client markets
strengthen the Board’s ability to guide product strategy,
partnership development, and delivery of shareholder value.
“Dr. Stefanelli adds a strong and experienced voice who will
press the business forward,” said Dr. Jason Myers, Owner and
Founder of G2G Ventures. “She is a true scientist and an expert in
the industry, with a career progression that includes research,
commercial development, product strategy and proven leadership at
all levels. Dr. Stefanelli understands our vision, and offers
perspective to help lead Navidea’s technology and assets to the
forefront.”
Dr. Stefanelli is currently the founding consultant of a
consulting practice focused on supporting Precision Medicine
Companies including genomics, digital pathology, artificial
intelligence, therapeutics, and medical devices as a Consultant,
Scientific Advisor, or Independent Board Member. Previously, her
experience includes serving as President, Board Member, and Chief
Business Officer at Paige, as Senior Vice President and Head of
Partnerships at Invitae/ArcherDX, as Clinical Commercial
Development Lead at Life Technologies, as a Genomics Specialist at
Roche Diagnostics, and in science and microbiology roles with
Genewiz, USDA APHIS and Sandia National Laboratories. Dr.
Stefanelli earned a B.S. in Animal Sciences & Industry, M.S. in
Food Science/Microbiology, and Ph.D. in Molecular Medicine and
Diagnostic Pathology within the Department of Diagnostic
Medicine/Pathobiology from the Veterinary School of Medicine at
Kansas State University. Her teaching experience includes
instruction related to veterinary virology, food microbiology and
automation in microbiology, and Dr. Stefanelli has published in
peer reviewed journals throughout her career.
Separately, Alexander L. Cappello, after having joined Navidea
in 2021 and recently serving as Chair of the Board, has decided to
step down to pursue opportunities outside the organization.
“We thank Mr. Cappello for his contribution,” said John K.
Scott, Jr, Navidea’s Vice Chair of the Board. “We wish him the very
best in pursuit of his next opportunity, and continue our focus on
developing processes and growth strategies led by Navidea’s team of
experts and our experienced partners in G2G Ventures.”
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is
developing multiple precision-targeted products based on its
Manocept platform to enhance patient care by identifying the sites
and pathways of disease and enable better diagnostic accuracy,
clinical decision-making, and targeted treatment. Navidea’s
Manocept platform is predicated on the ability to specifically
target the CD206 mannose receptor expressed on activated
macrophages. The Manocept platform serves as the molecular backbone
of Tc99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. Navidea’s strategy
is to deliver superior growth and shareholder return by bringing to
market novel products and advancing the Company’s pipeline through
global partnering and commercialization efforts. For more
information, visit www.navidea.com.
About G2G Ventures
G2G Ventures is a Colorado-based private equity firm focused on
empowering organizations to reach their full potential through
investment and consulting services. Specializing in creating
long-term partnerships with trusted investors and established
businesses, G2G Ventures draws on strong internal balance sheet
liquidity, augmented by trusted investor capital, to craft bespoke
capital solutions which include private equity investment, venture
capital participation, and mezzanine debt options. Beyond financial
investment, G2G Ventures provides accretive consulting services to
help clarify strategic goals and key performance indicators (KPIs),
evolve financial processes, and enhance operational effectiveness.
To learn more about how G2G Ventures is a growth partner for
enduring business, connect with our team.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. We have based these forward-looking statements largely on
our current expectations and projections about future events and
financial trends affecting the financial condition of our business.
Forward-looking statements include our expectations regarding
pending litigation and other matters. These forward-looking
statements are subject to a number of risks, uncertainties and
assumptions, including, among other things: our history of
operating losses and uncertainty of future profitability; the final
outcome of any pending litigation; our ability to successfully
complete research and further development of our drug candidates;
the timing, cost and uncertainty of obtaining regulatory approvals
of our drug candidates; our ability to successfully commercialize
our drug candidates; dependence on royalties and grant revenue; our
ability to implement our growth strategy; anticipated trends in our
business; our limited product line and distribution channels;
advances in technologies and development of new competitive
products; our ability to comply with the NYSE American continued
listing standards; our ability to maintain effective internal
control over financial reporting; the impact of the current
coronavirus pandemic; and other risk factors detailed in our most
recent Annual Report on Form 10-K and other SEC filings. You are
urged to carefully review and consider the disclosures found in our
SEC filings, which are available at http://www.sec.gov or at
http://ir.navidea.com.
Investors are urged to consider statements that include the
words “will,” “may,” “could,” “should,” “plan,” “continue,”
“designed,” “goal,” “forecast,” “future,” “believe,” “intend,”
“expect,” “anticipate,” “estimate,” “project,” and similar
expressions, as well as the negatives of those words or other
comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any
forward-looking statements, any of which could turn out to be
incorrect. We undertake no obligation to update publicly or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise after the date of this
report. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report
may not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230601006095/en/
Investor Relations Contact Navidea Biopharmaceuticals,
Inc. G2G Ventures - Executive Consultant Theodore Gerbick Chief
Marketing Officer tgerbick@g2g.ventures
Navidea Biopharmaceuticals (AMEX:NAVB)
過去 株価チャート
から 12 2024 まで 1 2025
Navidea Biopharmaceuticals (AMEX:NAVB)
過去 株価チャート
から 1 2024 まで 1 2025
